Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Modulation of TARP γ8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain.

Knopp KL, Simmons RMA, Guo W, Adams BL, Gardinier KM, Gernert DL, Ornstein PL, Porter W, Reel J, Ding C, Wang H, Qian Y, Burris KD, Need A, Barth V, Swanson S, Catlow J, Witkin JM, Zwart R, Sher E, Choong KC, Wall TM, Schober D, Felder CC, Kato AS, Bredt DS, Nisenbaum ES.

J Pharmacol Exp Ther. 2019 Jun;369(3):345-363. doi: 10.1124/jpet.118.250126. Epub 2019 Mar 25.

PMID:
30910921
2.

Extracellular signal-regulated kinases mediate the enhancing effects of inflammatory mediators on resurgent currents in dorsal root ganglion neurons.

Wu B, McDermott JS, Krajewski JL, Knopp KL, Nisenbaum ES, Cummins TR, Tan ZY.

Mol Pain. 2019 Jan-Dec;15:1744806919837104. doi: 10.1177/1744806919837104.

3.

Structural Determinants of the γ-8 TARP Dependent AMPA Receptor Antagonist.

Lee MR, Gardinier KM, Gernert DL, Schober DA, Wright RA, Wang H, Qian Y, Witkin JM, Nisenbaum ES, Kato AS.

ACS Chem Neurosci. 2017 Dec 20;8(12):2631-2647. doi: 10.1021/acschemneuro.7b00186. Epub 2017 Sep 5.

PMID:
28825787
4.

Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models.

Johnson MP, Muhlhauser MA, Nisenbaum ES, Simmons RM, Forster BM, Knopp KL, Yang L, Morrow D, Li DL, Kennedy JD, Swanson S, Monn JA.

Br J Pharmacol. 2017 May;174(9):822-835. doi: 10.1111/bph.13740. Epub 2017 Mar 13.

5.

Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism.

Kato AS, Burris KD, Gardinier KM, Gernert DL, Porter WJ, Reel J, Ding C, Tu Y, Schober DA, Lee MR, Heinz BA, Fitch TE, Gleason SD, Catlow JT, Yu H, Fitzjohn SM, Pasqui F, Wang H, Qian Y, Sher E, Zwart R, Wafford KA, Rasmussen K, Ornstein PL, Isaac JT, Nisenbaum ES, Bredt DS, Witkin JM.

Nat Med. 2016 Dec;22(12):1496-1501. doi: 10.1038/nm.4221. Epub 2016 Nov 7.

PMID:
27820603
6.

Protein kinase C enhances human sodium channel hNav1.7 resurgent currents via a serine residue in the domain III-IV linker.

Tan ZY, Priest BT, Krajewski JL, Knopp KL, Nisenbaum ES, Cummins TR.

FEBS Lett. 2014 Nov 3;588(21):3964-9. doi: 10.1016/j.febslet.2014.09.011. Epub 2014 Sep 19.

7.

Tetrodotoxin-resistant sodium channels in sensory neurons generate slow resurgent currents that are enhanced by inflammatory mediators.

Tan ZY, Piekarz AD, Priest BT, Knopp KL, Krajewski JL, McDermott JS, Nisenbaum ES, Cummins TR.

J Neurosci. 2014 May 21;34(21):7190-7. doi: 10.1523/JNEUROSCI.5011-13.2014.

8.

Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain.

Benschop RJ, Collins EC, Darling RJ, Allan BW, Leung D, Conner EM, Nelson J, Gaynor B, Xu J, Wang XF, Lynch RA, Li B, McCarty D, Nisenbaum ES, Oskins JL, Lin C, Johnson KW, Chambers MG.

Osteoarthritis Cartilage. 2014 Apr;22(4):578-85. doi: 10.1016/j.joca.2014.01.009. Epub 2014 Feb 6. Erratum in: Osteoarthritis Cartilage. 2014 Nov;22(11):1951. Nisenbaum, E S [added].

9.

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.

Upadhyaya HP, Desaiah D, Schuh KJ, Bymaster FP, Kallman MJ, Clarke DO, Durell TM, Trzepacz PT, Calligaro DO, Nisenbaum ES, Emmerson PJ, Schuh LM, Bickel WK, Allen AJ.

Psychopharmacology (Berl). 2013 Mar;226(2):189-200. doi: 10.1007/s00213-013-2986-z. Epub 2013 Feb 9. Review.

10.
11.

3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity.

Fisher MJ, Backer RT, Barth VN, Garbison KE, Gruber JM, Heinz BA, Iyengar S, Hollinshead SP, Kingston A, Kuklish SL, Li L, Nisenbaum ES, Peters SC, Phebus L, Simmons RM, van der Aar E.

Bioorg Med Chem Lett. 2012 Apr 1;22(7):2514-7. doi: 10.1016/j.bmcl.2012.02.003. Epub 2012 Feb 9.

PMID:
22386665
12.

Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation.

Timm DE, Benveniste M, Weeks AM, Nisenbaum ES, Partin KM.

Mol Pharmacol. 2011 Aug;80(2):267-80. doi: 10.1124/mol.110.070243. Epub 2011 May 4.

13.

Evolving cancer pain treatments: rational approaches to improve the quality of life for cancer patients.

Knopp KL, Nisenbaum ES, Arneric SP.

Curr Pharm Biotechnol. 2011 Oct;12(10):1627-43. Review.

PMID:
21466450
14.

Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists.

Yan LZ, Johnson KW, Rothstein E, Flora D, Edwards P, Li B, Li J, Lynch R, Vaughn R, Clemens-Smith A, McCarty D, Chow C, McKnight KL, Lu J, Nisenbaum ES, Mayer JP.

J Pept Sci. 2011 May;17(5):383-6. doi: 10.1002/psc.1358. Epub 2011 Mar 15.

PMID:
21412957
15.

Hippocampal AMPA receptor gating controlled by both TARP and cornichon proteins.

Kato AS, Gill MB, Ho MT, Yu H, Tu Y, Siuda ER, Wang H, Qian YW, Nisenbaum ES, Tomita S, Bredt DS.

Neuron. 2010 Dec 22;68(6):1082-96. doi: 10.1016/j.neuron.2010.11.026.

16.

Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.

Caraci F, Molinaro G, Battaglia G, Giuffrida ML, Riozzi B, Traficante A, Bruno V, Cannella M, Merlo S, Wang X, Heinz BA, Nisenbaum ES, Britton TC, Drago F, Sortino MA, Copani A, Nicoletti F.

Mol Pharmacol. 2011 Mar;79(3):618-26. doi: 10.1124/mol.110.067488. Epub 2010 Dec 15.

PMID:
21159998
17.

Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain.

Schuelert N, Zhang C, Mogg AJ, Broad LM, Hepburn DL, Nisenbaum ES, Johnson MP, McDougall JJ.

Osteoarthritis Cartilage. 2010 Nov;18(11):1536-43. doi: 10.1016/j.joca.2010.09.005. Epub 2010 Sep 21.

18.

TARPs differentially decorate AMPA receptors to specify neuropharmacology.

Kato AS, Gill MB, Yu H, Nisenbaum ES, Bredt DS.

Trends Neurosci. 2010 May;33(5):241-8. doi: 10.1016/j.tins.2010.02.004. Epub 2010 Mar 8. Review.

PMID:
20219255
19.

Methods for evaluation of positive allosteric modulators of glutamate AMPA receptors.

Siuda ER, Quirk JC, Nisenbaum ES.

Methods Mol Biol. 2007;403:37-57. doi: 10.1007/978-1-59745-529-9_3.

PMID:
18827986
20.

AMPA receptor subunit-specific regulation by a distinct family of type II TARPs.

Kato AS, Siuda ER, Nisenbaum ES, Bredt DS.

Neuron. 2008 Sep 25;59(6):986-96. doi: 10.1016/j.neuron.2008.07.034.

21.

New transmembrane AMPA receptor regulatory protein isoform, gamma-7, differentially regulates AMPA receptors.

Kato AS, Zhou W, Milstein AD, Knierman MD, Siuda ER, Dotzlaf JE, Yu H, Hale JE, Nisenbaum ES, Nicoll RA, Bredt DS.

J Neurosci. 2007 May 2;27(18):4969-77.

22.

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).

Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD.

J Pharmacol Exp Ther. 2007 Apr;321(1):308-17. Epub 2007 Jan 4.

PMID:
17204749
23.

Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease.

O'Neill MJ, Messenger MJ, Lakics V, Murray TK, Karran EH, Szekeres PG, Nisenbaum ES, Merchant KM.

Int Rev Neurobiol. 2007;77:179-217. Review. No abstract available.

PMID:
17178475
24.

Glutamate receptors and pain.

Bleakman D, Alt A, Nisenbaum ES.

Semin Cell Dev Biol. 2006 Oct;17(5):592-604. Epub 2006 Oct 28. Review.

PMID:
17110139
25.

A novel class of AMPA receptor allosteric modulators. Part 1: design, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives.

Fernandez MC, Castaño A, Dominguez E, Escribano A, Jiang D, Jimenez A, Hong E, Hornback WJ, Nisenbaum ES, Rankl N, Tromiczak E, Vaught G, Zarrinmayeh H, Zimmerman DM.

Bioorg Med Chem Lett. 2006 Oct 1;16(19):5057-61. Epub 2006 Aug 1.

PMID:
16879964
26.

A novel class of positive allosteric modulators of AMPA receptors: design, synthesis, and structure-activity relationships of 3-biphenyl-4-yl-4-cyano-5-ethyl-1-methyl-1H-pyrrole-2-carboxylic acid, LY2059346.

Zarrinmayeh H, Tromiczak E, Zimmerman DM, Rankl N, Ho KH, Dominguez E, Castaño A, Escribano A, Fernandez C, Jimenez A, Hornback WJ, Nisenbaum ES.

Bioorg Med Chem Lett. 2006 Oct 1;16(19):5203-6. Epub 2006 Jul 25.

PMID:
16872827
27.

A role for AMPA receptors in mood disorders.

Alt A, Nisenbaum ES, Bleakman D, Witkin JM.

Biochem Pharmacol. 2006 Apr 28;71(9):1273-88. Epub 2006 Jan 24. Review.

PMID:
16442080
28.

LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease.

O'Neill MJ, Murray TK, Clay MP, Lindstrom T, Yang CR, Nisenbaum ES.

CNS Drug Rev. 2005 Spring;11(1):77-96. Review.

29.

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).

Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD.

Psychopharmacology (Berl). 2005 Apr;179(1):271-83. Epub 2005 Feb 17.

PMID:
15717213
30.
31.

Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.

Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE.

Biochem Soc Trans. 2004 Nov;32(Pt 5):881-7. Review.

PMID:
15494040
32.

AMPA receptor potentiators for the treatment of CNS disorders.

O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES.

Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):181-94. Review.

PMID:
15180479
33.
34.

LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, O'Neill MJ.

J Pharmacol Exp Ther. 2003 Aug;306(2):752-62. Epub 2003 May 2.

PMID:
12730350
35.

Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex.

Zhai Y, George CA, Zhai J, Nisenbaum ES, Johnson MP, Nisenbaum LK.

Neuropsychopharmacology. 2003 Jan;28(1):45-52.

36.

A single residue contributes sensitivity to allosteric modulation of AMPA receptors by LY395153.

Quirk JC, Linden AM, Strakhova M, Yu H, Skolnick P, Nisenbaum ES.

Eur J Pharmacol. 2002 Nov 15;454(2-3):125-9.

PMID:
12421639
37.

LY404187: a novel positive allosteric modulator of AMPA receptors.

Quirk JC, Nisenbaum ES.

CNS Drug Rev. 2002 Fall;8(3):255-82. Review.

38.

Modulation of lateral perforant path excitatory responses by metabotropic glutamate 8 (mGlu8) receptors.

Zhai J, Tian MT, Wang Y, Yu JL, Köster A, Baez M, Nisenbaum ES.

Neuropharmacology. 2002 Aug;43(2):223-30.

PMID:
12213276
39.

AMPA receptor function is altered in GLUR2-deficient mice.

Harvey SC, Köster A, Yu H, Skolnick P, Baumbarger P, Nisenbaum ES.

J Mol Neurosci. 2001 Aug;17(1):35-43.

PMID:
11665861
40.

LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons.

Baumbarger P, Muhlhauser M, Yang CR, Nisenbaum ES.

Neuropharmacology. 2001 Jun;40(8):992-1002.

PMID:
11406190
41.
42.
43.

Selective blockade of a slowly inactivating potassium current in striatal neurons by (+/-) 6-chloro-APB hydrobromide (SKF82958).

Nisenbaum ES, Mermelstein PG, Wilson CJ, Surmeier DJ.

Synapse. 1998 Jul;29(3):213-24.

PMID:
9635891
44.
45.

Isolation and characterization of a persistent potassium current in neostriatal neurons.

Nisenbaum ES, Wilson CJ, Foehring RC, Surmeier DJ.

J Neurophysiol. 1996 Aug;76(2):1180-94.

PMID:
8871229
46.
47.
48.

Na+ influx through Ca2+ channels can promote striatal GABA efflux in Ca(2+)-deficient conditions in response to electrical field depolarization.

Bernath S, Zigmond MJ, Nisenbaum ES, Vizi ES, Berger TW.

Brain Res. 1993 Dec 31;632(1-2):232-8.

PMID:
8149231
49.
50.

Supplemental Content

Loading ...
Support Center